Brain Metastasis Clinical Trial
Official title:
A Phase II Trial to Evaluate the Use of Trental and Vitamin E for Prophylaxis of Radiation Necrosis
NCT number | NCT01508221 |
Other study ID # | BTC-W1 |
Secondary ID | |
Status | Completed |
Phase | Phase 2 |
First received | |
Last updated | |
Start date | June 2011 |
Est. completion date | February 1, 2017 |
Verified date | August 2023 |
Source | University of Cincinnati |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to determine whether the use of Trental and Vitamin E can help reduce the incidence of radiation necrosis (a lesion that usually occurs at the original tumor site) after radiosurgery. These two drugs are commonly used to treat radiation necrosis when it occurs but the hope is that these drugs can be used to prevent radiation necrosis from ever occurring.
Status | Completed |
Enrollment | 31 |
Est. completion date | February 1, 2017 |
Est. primary completion date | February 1, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Plan to undergo single or five fraction radiosurgery for a metastatic brain tumor - Diagnosis of a metastatic brain tumor may be accomplished by histologic confirmation or by clinical confirmation by the treating physician based on MR imaging characteristics in the setting of a known history of cancer - Age > 18 years - Partial or total resection of a metastatic tumor are eligible Exclusion Criteria: - Known sensitivity to vitamin E or Trental - Recent intracranial bleed or retinal hemorrhage - Treatment with a non-approved or investigational drug within 30 days before day 1 of study treatment - History of Avastin treatment - Anticipated need for treatment with Avastin - History of bleeding disorder - History of liver disorder |
Country | Name | City | State |
---|---|---|---|
United States | University of Cincinnati | Cincinnati | Ohio |
Lead Sponsor | Collaborator |
---|---|
University of Cincinnati |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants With Symptomatic Radiation Necrosis | Number of symptomatic death of healthy tissue caused by radiation therapy. | average 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT01913067 -
Evaluation of Cabazitaxel in Patients With Brain Metastasis Secondary to Breast Cancer and NSCLC
|
Phase 2 | |
Completed |
NCT02662725 -
Ipilimumab Combined With a Stereotactic Radiosurgery in Melanoma Patients With Brain Metastases
|
Phase 2 | |
Completed |
NCT00406835 -
Prospective Randomized Trial Between WBRT Plus SRS Versus SRS Alone for 1-4 Brain Metastases
|
Phase 3 | |
Completed |
NCT01724801 -
Icotinib or Whole Brain Irradiation in EGFR-mutant Lung Cancer
|
Phase 3 | |
Completed |
NCT00219297 -
Study of Patupilone in Patients With Brain Metastasis From Non-small Cell Lung Cancer
|
Phase 2 | |
Withdrawn |
NCT02328300 -
FLT PET/MR for Evaluation of Pseudoprogression in Patients With Brain Lesions
|
||
Terminated |
NCT01324635 -
Panobinostat and Stereotactic Radiation Therapy in Treating Patients With Brain Tumors
|
Phase 1 | |
Terminated |
NCT01894633 -
Study of Whole-brain Irradiation With Chloroquine for Brain Metastases
|
Phase 2 | |
Recruiting |
NCT02681549 -
Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer
|
Phase 2 | |
Terminated |
NCT02279992 -
Pilot Study of Vardenafil and Carboplatin in Patients With Gliomas and Brain Metastases
|
Early Phase 1 | |
Completed |
NCT02913534 -
Hypofractionated Stereotactic Radiation Therapy of Brain Metastases: Evaluation of Whole-brain Radiotherapy
|
N/A | |
Completed |
NCT01942980 -
Evaluation of the Efficacy of Hippocampal Avoidance on the Cognitive Toxicity of Whole-Brain Radiation Therapy After Surgical Resection of Single Brain Metastasis of Breast Cancer
|
Phase 3 | |
Terminated |
NCT01363557 -
Assess the Efficacy of Whole Brain Radiation Therapy in Lung Cancer Patients With Brain Metastasis
|
N/A | |
Active, not recruiting |
NCT05102747 -
Stereotactic Radiotherapy in Oligometastatic Brain Disease: a Randomised Phase III Study Comparing Hypofractionated Stereotactic Radiation Therapy (3*10 Gy) to the Historical Single-dose Radiosurgery (1*20 to 25 Gy) With Medico-economic Evaluation.
|
N/A | |
Recruiting |
NCT01891708 -
VEGFRs Predict Bevacizumab Benefit in Advanced Non Small Cell Lung Cancer
|
N/A | |
Completed |
NCT00587964 -
Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases
|
Phase 2 | |
Not yet recruiting |
NCT06462079 -
Sacituzumab Govitecan Combined With Head Radiotherapy for Her2-negative Breast Cancer Brain Metastases
|
Phase 2 | |
Not yet recruiting |
NCT02832635 -
A Clinical Trial on Whole-brain Radiotherapy With Temozolomide Concurrent Chemotherapy or Avoidance of Hippocampus for Patients of Brain Metastases
|
Phase 2 | |
Completed |
NCT01395407 -
Phase I Trial of Stereotactic Radiosurgery Following Surgical Resection of Brain Metastases
|
Phase 1 | |
Terminated |
NCT02433171 -
Methionine and PBR28-PET (Peripheral Benzodiazepine Receptors) in Brain Metastases Following Radiosurgery
|